Welcome to our dedicated page for Cullinan Oncology news (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Oncology stock.
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a clinical-stage biopharmaceutical company developing potential first- or best-in-class therapies for autoimmune diseases and cancer. The CGEM news feed highlights the company’s ongoing clinical progress, regulatory interactions, and scientific presentations across its portfolio of T cell engagers and targeted therapies.
News updates frequently cover clinical trial data for key assets such as CLN-049, an FLT3xCD3 bispecific T cell engager in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, and CLN-978, a CD19xCD3 bispecific T cell engager being studied in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s disease. Releases detail efficacy signals, safety profiles, B cell depletion data, and outcomes in high-risk patient subsets, often presented at major medical meetings like ASH, ASCO, ESMO, ACR, and WCLC.
The CGEM news section also features updates on zipalertinib (CLN-081/TAS6417), an EGFR tyrosine kinase inhibitor for non-small cell lung cancer with EGFR exon 20 insertion and other uncommon mutations, developed in collaboration with Taiho Oncology and Taiho Pharmaceutical. These stories include information on Breakthrough Therapy Designation, rolling New Drug Application submissions, and data from REZILIENT trials, including cohorts with active brain metastases.
Investors and followers of Cullinan Therapeutics can use this page to review corporate updates, SEC-related announcements furnished via press release, and portfolio decisions such as program prioritizations or discontinuations. For anyone tracking CGEM, the news feed provides a consolidated view of the company’s disclosed milestones, scientific progress, and regulatory steps across its autoimmune and oncology programs.
Cullinan Oncology (Nasdaq: CGEM) has announced a clinical update on its investigational oral EGFR inhibitor, CLN-081, during a webinar on June 4, 2021. The update will review safety and efficacy results from an ongoing Phase 1/2a trial for Non-Small Cell Lung Cancer (NSCLC) patients with EGFR Exon 20 insertion mutations. Data from this trial will also be presented at the 2021 ASCO Annual Meeting. The webinar and poster will take place on the same day, with the poster accessible for on-demand viewing starting at 9:00 am ET.
Cullinan Oncology, Inc. (Nasdaq: CGEM) reported its Q1 2021 financial results, highlighting cash reserves of $473 million as of March 31, 2021, significantly up from $210.2 million at year-end 2020. The company initiated a Phase 2a expansion of its Cullinan Pearl trial for NSCLC patients with EGFRex20ins mutations and plans to present updated data at the 2021 ASCO Annual Meeting. Q1 expenses included $12.4 million in R&D and $5.2 million in G&A. Net income was reported at $1.4 million, driven by $18.9 million revenue from its license agreement with Zai Lab.
Cullinan Oncology (Nasdaq: CGEM) has announced that CFO Jeff Trigilio will present at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 11:45 am EDT. The presentation will be accessible only to registered attendees through the Needham conference portal. Interested investors can schedule meetings with Trigilio by contacting their Needham representative. Cullinan Oncology is focused on developing a diversified pipeline of targeted and immuno-oncology therapeutic candidates to drive shareholder returns.
Cullinan Oncology reported its financial results for the year ended December 31, 2020, highlighting significant advancements in its clinical pipeline and financial metrics. The company completed a Series C financing of $131.2 million and an IPO raising $287.4 million, enhancing its cash position to $210.2 million. Clinical progress includes the initiation of Phase 2a for CLN-081 in NSCLC with promising outcomes. R&D expenses totaled $43.2 million, contributing to a net loss of $59.5 million, influenced by non-cash charges. Strategic hires and partnerships underscore Cullinan's commitment to advancing immuno-oncology assets.
Cullinan Oncology (Nasdaq: CGEM) has announced that its CEO, Owen Hughes, will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 AM EST. The presentation will be available on-demand for registered attendees starting at that time. Cullinan specializes in developing a diverse pipeline of targeted oncology and immuno-oncology therapies, focusing on candidates with novel technology and advanced development stages.
Cullinan Management, Inc. (Nasdaq: CGEM) has announced significant updates regarding its oncology pipeline. The company plans to expand enrollment in the Phase 1/2a trial of CLN-081 for NSCLC patients with EGFR exon 20 insertions, allowing 36 patients total. Cullinan has withdrawn its IND for CLN-049 in AML due to FDA feedback, while an IND submission for CLN-619 is planned for Q2 2021. CEO Owen Hughes will present at the SVB Leerink Global Healthcare Conference on February 26, 2021.
Cullinan Management (Nasdaq: CGEM) has successfully closed its initial public offering, selling 13,685,000 shares at $21.00 each, resulting in gross proceeds of $287.4 million. This offering included 1,785,000 shares exercised by underwriters. The shares started trading on the Nasdaq Global Select Market on January 8, 2021. Morgan Stanley, SVB Leerink, and Evercore served as joint book-running managers. The press release emphasizes Cullinan's focus on developing a robust pipeline of oncology and immuno-oncology therapies.
Cullinan Management has announced the pricing of its upsized initial public offering (IPO) of 11,900,000 shares at $21.00 per share, aiming to raise approximately $249.9 million before expenses. The underwriters also have a 30-day option to purchase an additional 1,785,000 shares. Shares will begin trading on the Nasdaq Global Select Market under the symbol “CGEM” on January 8, 2021, with the offering expected to close on January 12, 2021. Morgan Stanley, SVB Leerink, and Evercore Group are joint book-running managers for the offering.
Cullinan Management, a biopharmaceutical company, has announced the pricing of its upsized initial public offering of 11,900,000 shares at $21.00 each, aiming to raise approximately $249.9 million before expenses. The shares will begin trading on The Nasdaq under the symbol CGEM on January 8, 2021, with the offering expected to close on January 12, 2021. The company focuses on developing targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.